Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $126,305.74 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 4,213 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $29.98, for a total transaction of $126,305.74. Following the transaction, the chief financial officer now directly owns 128,365 shares of the company’s stock, valued at approximately $3,848,382.70. This trade represents a 3.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total value of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total value of $4,276,577.98.
• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.96, for a total transaction of $196,965.28.

Hims & Hers Health Trading Down 6.8 %

Shares of NYSE HIMS opened at $26.56 on Monday. The stock has a market cap of $5.80 billion, a PE ratio of 60.37 and a beta of 1.25. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The company has a 50-day moving average of $26.37 and a 200 day moving average of $21.47.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.04) earnings per share. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on HIMS. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Morgan Stanley started coverage on Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Finally, TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $22.80.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HIMS. Renaissance Technologies LLC grew its holdings in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after purchasing an additional 3,205,108 shares during the period. Wellington Management Group LLP grew its stake in shares of Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after buying an additional 883,230 shares during the period. Geode Capital Management LLC increased its holdings in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after buying an additional 482,177 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after buying an additional 328,142 shares during the period. Finally, Carnegie Investment Counsel acquired a new position in Hims & Hers Health in the third quarter valued at approximately $5,531,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.